Urinary ctx-ii is more useful in postmenopausal women than in men to detect radiological knee OA: the matsudai knee osteoarthritis survey  by Yamagiwa, H. et al.
Table 2
Average group intra-assay %CV for Sample Preparation Method.
Neat Digested 2xDilution 4xDilution
Luminex Polystyrene (n¼16) IL6 22.4 (IQR 18.8-29.9) (n¼7) 6.1 (IQR 3.8-13.7) (n¼15)
IL8 26.5 (SD 16.3) (n¼7) 4.8 (SD 1.8) (n¼13)
Luminex Magnetic (n¼7) IL6 28.2 (SD 9.4) 6.7 (SD 6.0) 26.0 (SD 16.5) 20.8 (SD 16.6)
Meso Scale Discovery (n¼7) IL6 6.6 (SD 2.5) 7.2 (SD 8.0) 13.3 (9.0) 14.2 (SD 13.0)
IL8 10.2 (SD 6.8) 10.9 (SD 6.2) 15.2 (SD 9.6) 15.8 (SD 13.2)
TNF-a 25.4 (SD 14.2) 14.5 (SD 5.9) 18.8 (SD 19.4) 27.0 (SD 16.4)
IL1b 55.3 (SD 37.6) 69.8 (SD 27.9) 67.6 (SD 29.0) 124.1 (SD 57.1)
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S85recommend sample pre-treatment with 2mg/ml hyaluronidase (& 2-fold
dilution) for multiplex synovial ﬂuid analysis.
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A WIDE ASSOCIATION STUDY OF PREDICTORS OF FUTURE KNEE PAIN:
DATA FROM THE OSTEOARTHRITIS INITIATIVE
J.I. Galván-Tejada 1, A. Martinez-Torteya 1, S. Totterman 2, J. Farber 2,
V. Treviño 1, J.G. Tamez-Pena 1. 1 ITESM, Monterrey, Nuevo Leon, Mexico;
2Qmetrics Technologies, Rochester, NY, USA
Purpose: Pain is a common symptom of knee OA. The presentation of
the symptom is protean, and varies from person to person and from
disease stage to disease stage. WOMAC pain sub scores assess a sub-
ject's pain while: 1) In bed; 2) Walking; 3) Climbing stairs; 4) Standing;
and 5) Lying down. These ﬁve categories reﬂect, presumably, different
etiologies of pain. To better understand the etiology of pain in these
settings, the OAI has been capturing thousands of variables (variable is
a speciﬁc clinical data) in OA patients; hopefully, evaluation of these
variables will allow a better understanding of OA, and establish
predictors of OA related pain. The objective of this work was to use
automated wide association tools to determine which OAI variables,
singularly or in association with other variables, best predict future OA
related pain.
Methods: The 4786 OAI enrolled subjects and the 1226 variables of the
OAI baseline clinical datasets (OAI:0.2.2) and the 36 month WOMAC pain
sub-score data (OAI:5.2.1) were explored in this study. Baseline variables
with more than 10% of missing information were removed. Subjects with
36 month missing WOMAC pain data were removed. Therefore, only
4204 patients and 629 variables were included in this study. Further-
more, to explore the no-pain related sources of future knee pain all
baseline pain related variables were removed. The max value from the
left and right knee pain sub-scores were used as the outcome variable to
be predicted by a ﬁve variable multidimensional nearest centroid clas-
siﬁer using BIOMATEC (Monterrey, Mexico). The top predictor variables
of each pain sub-score were selected after generating 5000 models using
a 33%, 67% split between training and testing sets. Once the top variables
were selected, linear models and R software were used to get the
signiﬁcance of those variables in predicting the 36 month WOMAC pain
scores.
Results: All linear regression models were highly signiﬁcant (p<1.0-
10) with R2 ranging from 0.199 to 0.328. Left knee catch or hand
up when moving, folate supplements, having a symptomatic knee,
physical scale and right knee stiffness score predicted pain while lying
down. Health limiting moderate activities, WOMAC knee stiffness, left
knee KOOS symptoms and blood pressure predicted pain in Bed.
Climbing stairs pain was predicted by lack of conﬁdence in knees and
WOMAC disability score. Health limiting moderate activities, left knee
swelling, lack of conﬁdence in knees and WOMAC stiffness score
predicted pain while walking. Standing pain was predicted by KOOS
symptom score and 400 meters walk time physical test.
Conclusions: Wide association studies can be very helpful in data
mining the OAI databases. These tools were used to explore models
predictive of the 36 month pain sub scores and yielded highly pre-
dicting models. Therefore, three year pain prognosis is possible using
clinical data.Ă
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URINARY CTX-II IS MORE USEFUL IN POSTMENOPAUSALWOMEN THAN
IN MEN TO DETECT RADIOLOGICAL KNEE OA: THE MATSUDAI KNEE
OSTEOARTHRITIS SURVEY
H. Yamagiwa 1, Y. Takahashi 2, T. Hayami 3, N. Tanishi 4, G. Omori 5,
Y. Koga 6, N. Endo 1. 1Dept. of Orthop. Surg., Niigata Univ., Niigata, Japan;
2Dept. of Orthop. Surg., Niigata Prefectural Central Hosp., Joetsu, Japan;
3Dept. of Orthop. Surg., Saiseikai Niigata Daini Hosp., Niigata, Japan;
4Dept. of Orthop. Surg., Niigata Rosai Hosp., Joetsu, Japan; 5Ctr. for
Transdisciplinary Res., Niigata Univ., Niigata, Japan; 6Dept. of Orthop. Surg.,
Niigata Med. Ctr. Hosp., Niigata, Japan
Purpose: Biochemical markers of cartilage degradation are important
indices to evaluate knee osteoarthritis (OA). The correlation between
radiological knee OA and urine CTX-II (C-terminal crosslinking telopeptide
of collagen type II: uCTX-II) needs to be evaluated how this marker is
useful in the health check-up in a large population-based study.
Methods: We have performed the epidemiological knee survey in a rural
Japanese population at the Matsudai district in Niigata Prefecture, Japan
since 1979. In 2010 (6th survey), a cross-sectional study of biomarkers was
conducted with informed consent. Urine specimens were collected from
942 subjects, and uCTX-II was measured using Urine CartiLaps EIA. The
data more than 1000 ng/mmmol Cre were considered as outliers. Subjects
with oral administration of bisphosphonate, fracture within a year, or TKA
were excluded. Standing knee AP X-rays were obtained and graded
according to the Kellgren-Lawrence (K-L) classiﬁcation. The 60- to 79-year-
old subjects were selected and then divided by gender (260 female and 276
male) and OA grade (K-L Grade 0,1, Grade 2, and Grade 3,4 groups). The
levels of uCTX-II were compared between three OA grade groups using
Kruskal-Wallis test and Mann-Whitney U-test. The subjects were stratiﬁed
into quartiles based on the values of uCTX-II, and proportion of OA grades
in each quartile was compared using chi-square test. In addition, to
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S86estimate the predictive value of uCTX-II, ROC curve analysis was employed
and area under the curve (AUC) was evaluated. p<0.05 was considered
statistically signiﬁcant.
Results: In female subjects, uCTX-II values signiﬁcantly increased according
to the severity of knee OA (Fig.1A). In male subjects, OA G3,4 group had
signiﬁcantly higher uCTX-II values than G0,1 group or G2 group (Fig.1B).
ĂFig 1. Relationship between knee X-ray OA grades and uCTX-II levels in (A)
female and (B) male subjects. Each box represents the 25th/50th (median)
to 75th percentiles. The lines outside the box represent the 10th and 90 th
percentiles. *; P<0.05. **; P<0.01, ***; P<0.001.
The mean levels of uCTX-II in each quartile were 152, 236, 345, 554 ng/
mmol Cre in female and 121, 188, 269, 469 in male. Higher quartiles (Q3
and Q4) of uCTX-II level included higher numbers of OA (G2) subjects in
female but not signiﬁcant in male (Fig.2).
ĂFig. 2 Quartiles by uCTX-II levels and proportion of OA grades in (A) female
and (B) male. Each quartile has 65 and 69 subjects in female and mal-
e.Signiﬁcant difference was observed only in female (p<0.0001,Chi-square).
ROC curve analysis for discriminating G2 OA showed that AUC was 0.65
and 0.61 in female and male, respectively. If cut-off is 300 in female,
sensitivity and speciﬁcity are 60 and 65 %, respectively.
Conclusions: uCTX-II is more useful in female older than 60 years but
a modest biomarker of knee OA X-ray grade by the single measurement in
the cross-sectional study. OA changes of other joints (e.g. lumbar spon-
dylosis) may affect the level of uCTX-II. Further analysis of longitudinal
changes of uCTX-II and knee OA grade using the data of 2007 (5th) and
2010 surveys is in progress.
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PERFORMANCE METRICS OF A NEWLY FORMATTED TYPE II COLLAGEN
CLEAVAGE NEO-EPITOPE ASSAY FOR HUMAN URINE: C2C-HUSA
J.L. Huebner 1, N. Ha 2, S. Bourdon 2, V.B. Kraus 1. 1Duke Univ. Med. Ctr.,
Durham, NC; 2 IBEX Pharmaceuticals, Inc, Montreal, QC, Canada
Purpose: The purpose of this studywas to evaluate the performancemetrics
of a new C2C sandwich immunoassay (IB-C2C-HUSA), including reproduc-
ibility and linearity as well as variation due to physical activity or food
consumption, to inform biospecimen collection protocols in clinical trials.
Type II collagen is themost abundant collagen inarticular cartilage, providing
tensile strength, and is cleaved by collagenases, resulting in the creation of
a neoepitope at the C terminus of the 3/4 length fragment, detectable in
human body ﬂuids by the C2C competitive ELISA. Once this initial cleavage
has occurred, proteases create subsequent degradation products containing
the C-terminal neoepitope that are detectable in human urine.
Methods: Forty participants with knee OA (20 patients for each of two
cohorts) were admitted overnight for serial urine sampling to assess the
variation of OA-related biomarkers. Urine samples were obtained on theevening (6-8PM) of Day 1 (T3; n¼34), prior to rising (8AM) from bed (T0;
n¼34), 1 hr after rising (9AM) without food consumption (T1a; n¼20), 1-2
hr after rising (9-10AM) with food consumption (T1; n¼34), and at noon, 4
hr after rising (T2; n¼14). Urine C2C was measured using the new IB-C2C-
HUSAand valueswere corrected for creatinine concentrations and reported
as ng/mmol Cr. The linearity of the assay was determined by testing each
urine sample at neat, 1:2, and 1:4 dilutions. The percent recovery was
calculated as the adjusted concentration versus the adjusted concentration
of the previous dilution. The acceptance criteria for linearity are between
70-130%. To assess for variation due to activity and food consumption across
the cohorts, the biomarker concentrations at each time point for each
subject were normalized to the mean concentration of the four time points
for that individual. Results were analyzed using non-parametric Friedman's
testwith Dunn's post-hocmultiple comparison test. To compare the results
of the newly formatted assay to the original C2C assay, correlation analyses
of the IB-C2C-HUSA toC2C valuesmeasuredpreviously in the same samples
was performed. Statistical analyses were performed using GraphPad soft-
ware and a p-value <0.05 was considered signiﬁcant.
Results: C2C was measurable in all urine samples using the new IB-C2C-
HUSA and values from analysis of neat samples were used for 98.5 percent
of the determinations. For samples that had concentrations higher than
the highest standard (5000 pg/ml), a dilution factor of 1:2 was used to
determine the ﬁnal concentration. The standard curve was linear
(R2¼0.992) and the assay was linear from neat to 1:4 dilutions with amean
percent recovery of 126%. The mean concentrations +SD and range for the
IB-C2C-HUSA biomarker at each time point (pg/ml) were as follows: T0:
1244+1055 (249-5246);T1a: 1635+1205 (344-5771); T1: 1871+1032 (443-
4952); T2: 1074+ (239-3213); T3: 1043+814 (240-3845). Whereas C2C
concentrations, uncorrected for urine creatinine, varied greatly within
a day (Fig 1A), C2C concentrations corrected for creatinine demonstrated
no statistically signiﬁcant variation of the biomarker with either activity
(T1a) or with food consumption (T1) (Fig 1B), the two conditions most
likely to affect sampling in a clinical trial. A comparison of values obtained
from the original C2C and the IB-C2C-HUSA assay at each time point
revealed a signiﬁcant correlation between the original and new formats for
T1a (p¼0.001, r2¼0.46), T1(p¼0.04, r2¼0.12) , and T2 (p¼0.03, r2¼0.33).
Conclusions: The new IB-C2C-HUSA immunoassay is a highly reproducible
sandwich assay that yielded measurable type II collagen neoepitope frag-
ments in all 136 samples tested. Compared with the original C2C compet-
itive ELISA, this new sandwich ELISA did not show variation due to activity.
This makes it useful for the measurement of collagen degradation in OA
studies, and in particular, it would be appropriate for analyses of legacy
samples, obtained without regard to standardization of time of collection.
Ă
159
ELEVATED EXPRESSION OF MMP9 IN PLASMA OF PATIENTS WITH
SYMPTOMATIC KNEE OSTEOARTHRITIC: CORRELATION WITH DISEASE
SEVERITY AND PROGRESSION
M. Attur 1, J.D. Greenberg 1, J. Todd 2, Q.A. Lu 2, R. Ramirez 2, C. Oh 3,
J. Samuels 1, S. Krasnokutsky 1, S.B. Abramson 1. 1NYUHosp. for Joint
Diseases, New York, NY; 2 Singulex, Alameda, CA; 3NYU-Dept. of
Environmental Med., New York, NY, USA
